natgillin/translations-raw huggingface dataset:
Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. 
Levetiracetam zavaruje pred napadi v širokem spektru živalskih modelov parcialnih in primarno generaliziranih napadov in ne deluje prokonvulzivno.
Management of overdose 
Obvladovanje prevelikega odmerjanja
Nevertheless, the concentration of this metabolite remains low. 
Kljub temu ostane koncentracija primarnega presnovka majhna.
Acute kidney injury 
Akutna poškodba ledvic
After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. 
Po akutnem prevelikem odmerjanju je mogoče želodec izprazniti z izpiranjem želodca ali sprožitvijo bruhanja.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome); 
• široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom)
The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications. 
Varnostni profil levetiracetama je v splošnem podoben v vseh starostnih skupinah (odrasli in pediatrični bolniki) in pri vseh odobrenih indikacijah za zdravljenje epilepsije.
• uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity); 
• nekontrolirani mišični spazmi, ki prizadanejo glavo, trup in okončine, težave pri nadzoru gibanja, hiperkinezija (hiperaktivnost)
Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. 
Bolnike je zato treba kontrolirati glede znakov depresije in/ali samomorilnega razmišljanja ali vedenja;
Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. 
Za probenecid (500 mg štirikrat na dan), ki blokira ledvično tubularno sekrecijo, je dokazano, da zavre ledvični očistek primarnega presnovka, ne pa levetiracetama.
The primary metabolite is inactive. 
Primarni presnovek ni aktiven.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. 
Otrokom z okvaro ledvic je treba odmerek levetiracetam prilagoditi glede na delovanje ledvic, kajti očistek tega zdravila je povezan z delovanjem ledvic.
Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. 
Največja koncentracija v plazmi (Cmax) je dosežena 1,3 ure po odmerku.
Take the oral solution following your doctor's instructions. 
Peroralno raztopino jemljite po zdravnikovih navodilih.
• Levetiracetam Actavis Group is used as a chronic treatment. 
• Zdravilo Levetiracetam Actavis Group se uporablja za kronično zdravljenje.
Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates. 
Sočasno jemanje katerega koli substrata alkoholdehidrogenaze lahko povzroči hude neželene učinke pri novorojenčkih.
Push the tip of the syringe into the adaptor opening. 
Potisnite konico brizge v odprtino nastavka.
(impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration); 
(motena usklajenost mišičnih gibov), parestezija (mravljinčenje), motnje pozornosti (izguba koncentracije)
Dose recommendations for infants from 6 months of age, children and adolescents: 
Priporočila za odmerjanje pri dojenčkih od 6. meseca starosti, otrocih in mladostnikih:
• anorexia (loss of appetite); 
• anoreksija (izguba teka)
The contents of the syringe can also be given directly from the syringe into the mouth or emptied onto a spoon (Figure 3). 
Vsebino brizge si lahko daste tudi neposredno v usta ali jo izpraznite na žlico (slika 3).
Dose adjustment is not required. 
Odmerka ni treba prilagoditi.
Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation. 
Primeri encefalopatije so se običajno pojavili na začetku zdravljenja (od nekaj dni do nekaj mesecev)
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]); 
• gripi podobne simptome in izpuščaj na obrazu, ki se v nadaljevanju razširi in ga spremlja visoka temperatura, zvišane vrednosti jetrnih encimov pri krvnih testih in povečanje števila določenega tipa belih krvnih celic (eozinofilija) ter povečane bezgavke (reakcija na zdravilo z eozinofilijo in sistemskimi simptomi [DRESS]
• symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function; 
• simptome kot so nizek volumen urina, utrujenost, slabost, bruhanje, zmedenost in otekanje nog, gležnjev ali stopal saj so lahko to znaki nenadnega zmanjšanja delovanja ledvic
In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. 
Pri bolnikih s hudo okvaro jeter lahko očistek kreatinina podceni stopnjo odpovedi ledvic.
• If you notice any slow down in the growth or unexpected puberty development of your child, 
• Če pri otroku opazite upočasnitev rasti ali nepričakovan pojav pubertete, se posvetujte z zdravnikom.
Levetiracetam is a highly soluble and permeable compound. 
Levetiracetam je zelo topna in permeabilna spojina.
Should your doctor decide to stop your Levetiracetam Actavis Group treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis Group. 
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Levetiracetam Actavis Group, vam bo dal napotke o postopni ukinitvi zdravila Levetiracetam Actavis Group.
To measure the dosing quantity, use one hand to hold the dosing body and the other hand to pull up the plunger until you reach the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (Figure 1). 
Da boste odmerili potrebni odmerek, z eno roko primite telo odmerne brizge in z drugo roko izvlecite njen bat, dokler ne doseže odmerne oznake, ki ustreza količini v mililitrih (ml), kakršno je predpisal zdravnik (slika 1).
In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2). 
Bolnikom s hudo okvarjenim delovanjem jeter je pred izbiro odmerka priporočljivo oceniti delovanje ledvic (glejte poglavje 4.2).
Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. 
Levetiracetam v odmerku 2.000 mg na dan ni vplival na farmakokinetiko digoksina in varfarina; protrombinski čas se ni spremenil.
Monotherapy for adults and adolescents from 16 years of age 
Monoterapija za odrasle in mladostnike od 16. leta starosti
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. 
Profil neželenih učinkov, ki je opisan spodaj, temelji na analizi združenih s placebom nadzorovanih kliničnih preskušanj za vse preučevane indikacije, v katerih so z levetiracetamom zdravili 3.416 bolnikov.
Empty the contents of the syringe in a glass of water by pushing down the plunger. 
Izpraznite vsebino brizge v kozarec vode, tako da bat potisnete navzdol.
The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies. 
Odmerek 1.800 mg/kg/dan je povzročil izrazito toksičnost pri samicah-materah in zmanjšanje telesne mase plodov v povezavi z večjo incidenco plodov s kardiovaskularnimi oziroma skeletnimi anomalijami.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na začetku zdravljenja ali po povečanju odmerka lahko neželeni učinki, npr. zaspanost, utrujenost in omotičnost, so lahko pogostejši na začetku zdravljenja in po povečanju odmerka.
In adults, levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. 
Pri odraslih je bila učinkovitost levetiracetama dokazana v 3 dvojno slepih, s placebom kontroliranih študijah z odmerki 1.000 mg, 2.000 mg ali 3.000 mg/dan, uporabljenih v dveh deljenih odmerkih, in s trajanjem zdravljenja do 18 tednov.
• diplopia (double vision), vision blurred; 
• diplopija (dvojni vid), zamegljen vid
Rhabdomyolysis and blood creatine phosphokinase increased* 
mialgija rabdomioliza in zvišanje kreatin fosfokinaze v krvi*
Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. 
Levetiracetam se lahko med nosečnostjo uporablja samo, če zdravnik po skrbnem pretehtanju ugotovi, da je to potrebno.
Oral absolute bioavailability is close to 
Absolutna peroralna biološka uporabnost je skoraj 100 %.
There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. 
Opisani so bili posamezni primeri zmanjšane učinkovitosti levetiracetama, če je bilo sočasno s peroralnim levetiracetamom uporabljeno osmotsko odvajalo makrogol.
The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. 
Navidezni telesni očistek levetiracetama in njegovega primarnega presnovka je koreliral z očistkom kreatinina.
The patients were randomized to carbamazepine CR 400 - 1,200 mg/day or levetiracetam 1,000 - 3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response. 
Bolniki so bili randomizirani na karbamazepin CR od 400 do 1.200 mg/dan ali na levetiracetam od 1.000 do 3.000 mg/dan, zdravljenje pa je trajalo do 121 tednov, odvisno od odziva.
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances. 
Zdravilna učinkovina levetiracetam je pirolidinski derivat (S-enantiomer α-etil-2-okso-1pirolidinacetamida) in kemično ni soroden obstoječim antiepileptičnim učinkovinam.
At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. 
Pri odmerku 3.600 mg/kg/dan so samo v eni od obeh študij embrio-fetalnega razvoja ugotovili rahlo zmanjšanje plodove mase v povezavi z mejnim povečanjem skeletnih sprememb/manjših anomalij.
• amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia 
• amnezija (izguba spomina), oslabljen spomin (pozabljivost), poslabšana koordinacija/ataksija
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. 
V tej študiji so bolnikom predpisali dnevni odmerek peroralne raztopine 20 mg/kg, 25 mg/kg, 40 mg/kg ali 50 mg/kg na podlagi sheme titriranja za njihovo starost.
Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. 
Razen tega so študije in vitro pokazale, da se levetiracetam veže na specifično mesto v možganskem tkivu glodalcev.
43.6% of the levetiracetam treated patients and 19.6% of the patients on placebo were considered as responders. 
Kot odzivnih je bilo ocenjenih 43,6 % prejemnikov levetiracetama in 19,6 % prejemnikov placeba.
What you need to know before you take Levetiracetam Actavis Group Do not take Levetiracetam Actavis Group 
Kaj morate vedeti, preden boste vzeli zdravilo Levetiracetam Actavis Group Ne jemljite zdravila Levetiracetam Actavis Group
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years. 
Da bi zagotovili točnost odmerjanja, je treba to pakiranje predpisati dojenčkom in majhnim otrokom v starosti od 6 mesecev do manj kot 4 leta.
Therefore there is no need for plasma level monitoring of levetiracetam. 
Zato koncentracije levetiracetama v plazmi ni treba kontrolirati.
Pull the plunger down and fill the syringe with a quantity of solution slightly beyond the prescribed dose (Figure 5). 
Potegnite bat dol in napolnite brizgo s količino raztopine, ki je malenkost večja od predpisanega odmerka (slika 5).
Instruction for use: Instruction for use for 10 ml syringes 
Navodilo za uporabo 10-ml brizg
A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation). 
Pri odraslih in otrocih so ugotovili pomembno korelacijo med koncentracijo v slini in plazmi (razmerje koncentracij slina/plazma je segala od 1 in 1,7 za peroralne tablete in za peroralno raztopino 4 ure po odmerku).
No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy. 
Pri dojenčkih z epilepsijo, mlajših od 12 mesecev niso ugotovili nobenih novih pomislekov glede varnosti za levetiracetam.
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 
Skupno 190 bolnikov, starih od 1 meseca do manj kot 4 leta, so zdravili z levetiracetamom v s placebom nadzorovanih in odprtih, razširjenih študijah.
This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product. 
Ta izsledek kaže, da bi interakcija med levetiracetamom in sinaptično vezikularno beljakovino 2A lahko pripomogla k antiepileptičnemu mehanizmu delovanja tega zdravila.
Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. 
Največja koncentracija v plazmi je bila dosežena od 0,5 do 1,0 uro po uporabi.
Levetiracetam Actavis Group is used: on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. 
Zdravilo Levetiracetam Actavis Group se uporablja: • sàmo za zdravljenje pri odraslih in mladostnikih od 16. leta starosti z novodiagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
The mean total body clearance was 0.96 ml/min/kg. 
Povprečni skupni telesni očistek je 0,96 ml/min/kg.
What Levetiracetam Actavis Group is and what it is used for What you need to know before you take Levetiracetam Actavis Group How to take Levetiracetam Actavis Group Possible side effects 
Kaj je zdravilo Levetiracetam Actavis Group in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Levetiracetam Actavis Group Kako jemati zdravilo Levetiracetam Actavis Group
Add-on therapy for infants aged 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg 
Dodatno zdravljenje dojenčkov, starih od 6 do 23 mesecev, otrok (v starosti od 2 do 11 let) in mladostnikov (v starosti od 12 do 17 let) s telesno maso manj kot 50 kg
Open the bottle and push the syringe adaptor firmly into the bottle neck (Figure 1). 
Odprite stekleničko in nastavek brizge trdno potisnite v vrat stekleničke (slika 1).
For children aged 6 months to less than 4 years 
Za otroke, stare od 6 mesecev do manj kot 4 leta
1,500 mg twice daily (1) Children 25 kg or less should preferably start the treatment with Levetiracetam Actavis Group 
1.500 mg dvakrat na dan (1) Pri otrocih s telesno maso 25 kg ali manj je treba zdravljenje po možnosti začeti z zdravilom
The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo. 
Podatki in vitro in podatki o medsebojnem delovanju s peroralnimi kontraceptivi, digoksinom in varfarinom in vivo kažejo, da in vivo ni pričakovati bistvene indukcije encimov.
In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product. 
V obeh populacijskih farmakokinetičnih analizah se je navidezni očistek levetiracetama v primeru sočasne uporabe s kakšnim antiepileptičnim zdravilom, ki inducira encime, povečal za približno 20 %.
Dose in children and adolescents 50 kg or more is the same as in adults. 
Odmerek za otroke in mladostnikih s telesno maso 50 kg ali več je enak kot za odrasle.
In this study, the patients received levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing). 
V tej študiji so bolniki prejemali stalen odmerek levetiracetama 60 mg/kg/dan (uporaba dvakrat na dan).
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction; 
• šibkost, vrtoglavico ali omotico ali težave z dihanjem, saj so to lahko znaki resne alergijske
Adverse reactions reported in clinical studies (adults, adolescents, children and infants> 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. 
Tabelirani seznam neželenih učinkov Neželeni učinki, opisani v kliničnih študijah (pri odraslih, mladostnikih, otrocih in dojenčkih, starejših od 1 meseca) in med obdobjem trženja, so navedeni v spodnji preglednici po organskih sistemih in pogostnosti.
Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. 
Levetiracetam in sorodni analogi kažejo ranžirno razvrstitev afinitete za vezavo na sinaptično vezikularno beljakovino 2A, ki korelira z jakostjo antiepileptične zaščite pri mišjem audiogenem modelu epilepsije.
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants aged 1 month to less than 6 months. 
Da bi zagotovili točnost odmerjanja, je treba to pakiranje predpisati dojenčkom v starosti od 1 meseca do manj kot 6 mesecev.
The fractional removal of levetiracetam was 51% during a typical 4-hour dialysis session. 
Frakcijska odstranitev levetiracetama med tipično 4-urno dializo je 51 %.
Dose in children 50 kg or greater is the same as in adults. 
Odmerek za otroke s telesno maso 50 kg ali več je enak kot za odrasle.
Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. 
Spremembe odmerka ne smejo preseči povečanja ali zmanjšanja 10 mg/kg dvakrat na dan vsaka dva tedna.
Two embryo-foetal development (EFD) studies were performed in rats at 400, 1,200 and 3,600 mg/kg/day. 
Pri podganah sta bili opravljeni dve študiji embrio-fetalnega razvoja z odmerki 400, 1.200 in 3.600 mg/kg/dan.
In this study, levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses. 
V tej študiji je bil odmerek levetiracetama 3.000 mg/dan za odrasle in mladostnike ter 60 mg/kg/dan za otroke; uporabljen je bil v 2 deljenih odmerkih.
Turn the bottle the right way up and remove the syringe (Figure 8). 
Stekleničko zdaj obrnite v pokončen položaj in odstranite brizgo (slika 8).
Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day. 
Štiri študije embrio-fetalnega razvoja so bile opravljene na kuncih v odmerkih 200, 600, 800, 1.200 in
Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam. 
Sočasna uporaba z digoksinom, peroralnimi kontraceptivi in varfarinom ni vplivala na farmakokinetiko levetiracetama.
• muscle weakness, myalgia (muscle pain); 
• šibkost mišic, mialgija (bolečina v mišicah)
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
Če imate dodatna vprašanja o uporabi zdravila, se posvetujte s svojim zdravnikom ali s farmacevtom .
Sixty of these patients were treated with levetiracetam in placebo-controlled studies. 
Od tega so 60 bolnikov zdravili z levetiracetamom v s placebom nadzorovanih študijah.
Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. 
Ugotovili so linearna in odmerku sorazmerna povečanja največje koncentracije v plazmi in površine pod krivuljo.
No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite. 
In vivo niso ugotovili enantiomerne interkonverzije ne pri levetiracetamu ne pri njegovem primarnem presnovku.
Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). 
Učinkovitost levetiracetama je bila ugotovljena v 24-tedenski dvojno slepi, s placebom kontrolirani študiji, ki je zajela odrasle, mladostnike in majhno število otrok z idiopatsko generalizirano epilepsijo s primarno generaliziranimi tonično kloničnimi (PGTC) napad v različnih sindromih (juvenilna monoklonična epilepsija, juvenilna epilepsija z absencami, otroška epilepsija z absencami ali epilepsija z napadi grand mal ob prebujanju).
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. 
Dokazano je, da levetiracetam in njegov primarni presnovek in vitro ne zavirata aktivnosti glavnih izooblik človeškega jetrnega citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 in 1A2),
Pull the syringe by the dosing body out of the bottle (Figure 2). 
Brizgo za njeno telo potegnite iz stekleničke (slika 2).
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, the following formula: 
Clcr v ml/min je mogoče pri odraslih in mladostnikih s telesno maso 50 kg ali več oceniti iz koncentracije kreatinina v serumu (mg/dl) po naslednji formuli:
Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. 
Po večkratni peroralni uporabo (odmerki od 20 do 60 mg/kg/dan) pri otrocih z epilepsijo (starih od 4 do 12 let) se je levetiracetam hitro absorbiral.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, noninferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Učinkovitost levetiracetama v monoterapiji je bila ugotovljena v dvojno slepi študiji vzporednih skupin za oceno neinferiornosti s karbamazepinom z nadzorovanim sproščanjem (CR - controlled release) pri 576 bolnikih, starih 16 let ali več z novoodkrito ali nedavno odkrito epilepsijo.
• a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme); 
• kožni izpuščaj, ki lahko tvori mehurčke in po videzu spominja na majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem)
• hair loss, eczema, pruritus; 
• izguba las, ekcem, pruritus